PHILADELPHIA, Jan. 15, 2019 /PRNewswire/ -- Group K Diagnostics (GKD), a biotechnology innovator aiming to overhaul the diagnostic process for both patient and caregiver, has concluded its time at the 37th Annual J.P. Morgan Healthcare Conference with a log of successful business meetings and a number of discussions around the company's exponential growth, accomplishments in 2018 and aspirational goals for 2019.
Since November of 2018, GKD has raised $2 million in Series A funding, entered into Part II of its liver function clinical trial at the University of Pennsylvania Liver Disease Clinic, moved into a new headquarters with a combined lab, manufacturing and office space, and prepared its submission to the FDA. GKD completed its liver function inpatient FDA clinical trials at Penn Medicine on December 21, 2018, and will submit findings to the FDA once the government reopens. Initial findings from the trial report that each liver function test had an accuracy rate of 98% or higher for whole blood testing.
"Discussions at the show were centered around the momentum we've built leading up to the J.P. Morgan conference and our plans for 2019," said Brianna Wronko, CEO at GKD.
Emilia Lopez-Ona, Chief Strategy Officer, added, "The feedback we received indicates that many industry players believe we have something special, and we're very excited to continue on our ambitious path of growth and innovation as we work to bring our revolutionary product to market."
GKD is now in pre-clinical trials for its comprehensive metabolic panel, and will be announcing a new clinical partnership in the coming weeks.
With over 9,000 attendees from more than 450 companies, the annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
About Group K Diagnostics
Group K Diagnostics (GKD) is a biotechnology innovator aiming to overhaul the diagnostic process for both patient and caregiver. The company's microfluidic point-of-care device, the MultiNostic, is capable of delivering results in just 20 minutes for more than 60 blood tests, streamlining the logistical process historically associated with lab work, maximizing patient-care transparency and allowing physicians to adjust medical treatments in a timely manner. The MultiNostic is currently undergoing clinical trials for liver function and full metabolic panels, and is pending FDA approval. Backed by a well-comprised syndicate of Mid-Atlantic investors and investment groups, the company has raised $2.8 million and is valued at more than $20 million. GKD is headquartered in Philadelphia and has a full development team based in India. For more information, visit GroupKDiagnostics.com.
Media Contact: Kim Cox
215-867-8600 ext. 220
SOURCE Group K Diagnostics